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Abstract: Epstein-Barr virus (EBV) is a clinically important human virus associated with several
cancers and is the etiologic agent of infectious mononucleosis. The viral nuclear
antigen-1 (EBNA1) is central to the replication and propagation of the viral genome and
likely contributes to tumourigenesis. We have compared EBNA1 homologues from
other primate lymphocryptoviruses (LCV) and found that the central glycine/alanine
repeat (GAr) domain, as well as predicted cellular protein (USP7 and CK2) binding
sites are present in homologues in the Old World primates, but not the marmoset;
suggesting that these motifs may have co-evolved. Using the resolved structure of the
C-terminal one third of EBNA1 (homodimerisation and DNA binding domain), we have
gone on to develop monomeric and dimeric models in silico of the full length protein.
The C-terminal domain is predicted to be structurally highly similar between
homologues, indicating conserved function. Zinc could be stably incorporated into the
model, bonding with two N-terminal cysteines predicted to facilitate multimerisation.
The GAr contains secondary structural elements in the models, while the protein
binding regions are unstructured, irrespective of the prediction approach used and
sequence origin. These intrinsically disordered regions may facilitate the diversity
observed in partner interactions. We hypothsise that the structured GAr could mask the
disordered regions, thereby protecting the protein from default degradation. In the
dimer conformation, the C-terminal tails of each monomer wrap around a proline-rich
protruding loop of the partner monomer, providing dimer stability, a feature which could
be exploited in therapeutic design.
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Supplementary Figure S1. Folding 
propensity of EBNA1.  
EBNA1 primary amino acid sequences from 
the primate LCVs* (as indicated) were used to 
predict the propensity of the proteins to fold by 
FoldIndex. FoldIndex uses hydrophobicity 
values and absolute net charge of the residues 
to predict structural and unstructured 
components of proteins. (GlobPlot2.3 employs 
defined propensity scales (based upon 
empirical protein structure data) in prediction). 
The distribution of hydrophobic and charged 
residues across the protein length are shown by 
blue and pink lines (respectively). Regions 
predicted to be disordered or structured are 
represented by negative (red) or positive 
(green) values (respectively). A simplified 
domain structure is indicated as a coloured bar 
above each plot: black: N-terminal; yellow: 
GAr; cyan: GR2 and protein binding sites; 
green: DNA binding and dimerisation. Residue 
number is given on the X axis. 
Note: the GAr is predicted to be structured in 
each case. Also note, a small region within the 
CK2 binding domain (within the section 
indicated by a cyan bar) in cy-EBNA1, rh-
EBNA1 and ba-EBNA1 is predicted to be 
structured (unlike hu-EBNA1) within the 
largely disordered stretch. This region maps to 
the extended CK2 binding site found in the 
Old World monkey sequences (see figure 2 of 
the manuscript). 
*EBNA1 homologues were only identified in 
primate LCVs. Text mining identified several 
proteins from rice (Oryza sativa) that are 
annotated as EBNA1 or EBNA1-like. 
Similarly, some bacterial sequences (for 
example from Erwinia chrysanthemi) are also 
annotated as EBNA1-nuclear protein. None of 
these sequences show a significant BLAST 
score (<10-50), or can be aligned with the LCV 
EBNA1 pro te ins (da ta no t shown) . 
Additionally, using reciprocal BLAST, none of 
these proteins show similarity with LCV 
EBNA1. 
	  
Table S1 ITASSER MOE Composite 
Ramachandran plot 
outliers 
7.98% 4.85% 4.07% 
Ramachandran plot 
favoured region 
73.1% 80.6% 89.5% 
RMSD with 1B3T 0.4Å 1.05Å 1.29Å 
Bad bonds 0 0.31% 0 
Bad angles 1.09% 1.72% 0.62% 
QMEANnorm score 0.14 0.09 0.15 
Supplementary Figure S2. EBNA1 model comparison.  
The EBV B95-8 EBNA1 sequence was input to I-TASSER, which selected the EBNA1 C-terminal 
domain crystal structure (1B3T) and several fragment templates comprising: yeast fatty acid 
synthetase (2PFF), a-L-fucosidase (2Z8X), photosynthetic reaction centre (1C51), type A collagen 
(1YOF) and dimeric 6-phosphoglucouronate dehydrogenase (2ZYD). The 1B3T template was also 
used to generate models in MOE. EBNA1 models constructed using I-TASSER and MOE (and the 
composite of these two generated in Modeller9v8 (shown above), were assessed for structural 
plausibility using Molprobity and QMEAN score servers (table S1). Models were superimposed 
over the template (1B3T) and RMSD was estimated for each. The qualitative model energy 
analysis, normalised (QMEANnorm) score of a protein structural model provides a composite 
scoring function based on several geometrical aspects, both global (for the entire structure) and 
local (per residue), enabling the discrimination of good and bad models. A score in the range of 0 to 
1.0 reflects a good model (optimally towards 0.5) and outside of this range (negative values or >1) 
reflects a poor model (for a non-membrane protein). While the composite model shows greater 
difference from 1B3T (RMSD), in all other respects it is better than either primary model. Overall 
the composite model shows more structural similarity to the I-TASSER primary model than to the 
MOE primary model. (I-TASSER has been ranked number 1 for several years in the CASP contest 
(critical assessment of protein structure prediction) http://predictioncenter.org/) 
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Supplementary Figure S3. Ramachandran 
Plots of EBNA1 modeled structures. 
The human and other primate LCV EBNA1 
protein structure models (as indicated)  were 
evaluated for dihedral bond angle (Phi and 
Psi) distribution using Ramachandran plots. 
Residues in allowed and disallowed regions  
are represented by green and pink spots 
(respectively). Generously and strictly 
allowed regions are depicted by fuchsia and 
cyan contour lines (respectively). The hu-
EBNA1 (B95-8 strain) composite model 
shows 89.5% of residues within the allowed 
region and an additional 5.9% in the 
generously allowed region. Given the 
proportion of Gly and Pro residues, these 
values are well within plausible limits. 
	  
Supplementary Figure S4. Comparison of the C-terminal region of the EBNA1 composite 
model and the resolved structure.  
The C-terminal region of the composite EBNA1 model (cyan) is shown superimposed over a 
monomer extracted from the resolved template 1B3T (yellow), from two angles (with a 
horizontal rotation of 90o). The RMSD value is 1.29Å. Note: the proline rich loop protrudes 
from both structures (right view). 
proline rich loop 
Legend to Supplementary Figure S5. Sequence alignment between hu-EBNA1 and cy-
EBNA1. 
The sequences of hu-EBNA1 (EBV/HHV4 B95-8) and cy-EBNA1 (Cyno-EBV/CEBV TsB-
B6) are shown aligned. The distribution of structural elements observed in the in silico models 
of each are shown as cylinders (α helices) and arrows (β sheets) in maroon (hu-EBNA1) and 
yellow (cy-EBNA1). Note: the modelled additional β sheets in the elongated potential CK2 
binding site of cy-EBNA1 (starting at residue 348) in comparison to hu-EBNA1. 
Supplementary Figure S5 
Supplementary Figure S6. EBNA1 MOE model bound with DNA. 
The hu-EBNA1 dimer model developed using MOE (using spatial constraints for DNA binding) 
is shown. Each monomer is represented in ribbon format (brown and cyan) while DNA is 
shown in surface format (yellow). Since the C-terminal region of the dimer is modelled by 
homology, the resulting model is structurally highly similar to the 1B3T template 
(superimposition of the MOE-dimer model with 1B3T gives an RMSD value of 0.35 Å).  
Shown above: the model with 180o horizontal rotation and beneath: with 90o rotation. Note: the 
string of residues connecting the C-terminal DNA binding and dimerisation domain with the 
remainder of the protein lies in the major groove of the DNA. Several features of dimer stability 
of the full length EBNA1 SymmDock-dimer were compared with a C-terminal tail (residues 
608 to 641) deleted SymmDock-dimer model (tabulated). GCS: geometrical complimentarity 
score (the higher, the more symmetrical the dimer); ACE: atomic contact energy; G: free energy 
(the lower, the more stable). 
Dimer	  
Model:	  
feature	  
Full	  
length	  
Tail	  
deleted	  
GCS	   17890	   13654	  
ACE	   -­‐1062.7	   -­‐398	  
G	   -­‐11094.65	   -­‐9562	  
Supplementary Table S2. 
Several features of dimer stability of the full length EBNA1 composite-dimer were compared 
with a C-terminal tail (residues 608 to 641) deleted SymmDock-dimer model (tabulated). GCS: 
geometrical complimentarity score (the higher, the more symmetrical the dimer); ACE: atomic 
contact energy; G: free energy (the lower, the more stable). 
Legend to Supplementary Figure S7. Secondary structure distribution of EBNA1 models. 
The distribution of the secondary structural elements of the different hu-EBNA1 models is 
shown above the primary sequence of EBV B95-8 EBNA1 (as assessed by HERA plot). The 
composite model (maroon), each MOE monomer in the dimer model (blue) and the GAr deleted 
composite model (green) are compared. Selected protein domains or interaction sites are 
indicated by coloured horizontal bars: purple: GR1 and GR2; yellow: GAr; orange: NLS; cyan: 
CK2 binding site; red: USP7 binding site; green: DNA binding and dimerisation domain. 
Coloured dots above the sequence indicate other noted residues: blue: predicted 
phosphorylation sites; pink: critical residues involved in USP7 binding; purple: dimerisation; 
green: DNA binding.  
Supplementary Figure S7 
Supplementary Figure S8. Comparison of composite dimer EBNA1 model with the 
resolved structure. 
The composite EBNA1 dimer model (blue) is shown superimposed over the resolved structure 
1B3T (brown) (RMSD value 1.5 Å). One side of the β barrel (right side from the viewed angle) 
was used as the reference point to align the dimers. It can be seen that the modelled dimer 
shows an altered angle between the monomers (compared to 1B3T), such that the β barrel is 
slightly wider (seen here by the slight misalignment on the left side). 
Supplementary Figure S9. The proline 
rich loops in the dimer.  
“Top” view of the resolved EBNA1 1B3T 
dimer showing the protruding proline rich 
loops. Each monomer/loop is differently 
coloured green/red and silver/mauve.  
Supplementary Figure S10. GAr deleted EBNA1 Model. 
Deletion of the GAr of hu-EBNA1 allows increased expression of the protein in heterologous 
systems and retains several of the protein’s functions. A composite monomeric model of GAr-
deleted hu-EBNA1 sequences was generated as for full length (using I-TASSER, MOE and 
Modeller). Removal of GAr impacts the predicted structure of the N terminal half, showing alpha 
helices in the CK2 and USP7 binding domains. Interestingly, three of the hydrogen bonds seen in 
1B3T that are absent or differently paired in the full length model (such as Arg469-Glu556) are 
present in the dimer model of the GAr deleted EBNA1 (manuscript table 2). The composite model 
of GAr deleted EBNA1 is shown in both ribbon format (above) and surface view (below) with 
180o rotations. The boxed region (above left) indicates the region which has been resolved (in 
1B3T). The C-terminal DNA binding and dimerisation domain of the model conforms to the 
resolved 1B3T structure used as the original template. The surface topology images are coloured 
to show structural and/or functional domains (as defined in figure 2): yellow: GAr; purple: GR1 
and GR2; pink: Arg71 and Arg72; cyan: CK2 interaction region; orange: NLS; red: USP7 binding 
site; light green and dark green: flanking region and core DNA binding and dimerisation domain.  
Supplementary Figure S11. GAr 
deleted EBNA1 homodimer. 
The GAr deleted composite EBNA1 
monomer model was used to generate 
a dimer in SymmDock. In this model, 
a longer alpha helix is predicted within 
the C-terminal tail and as such it does 
not form a complete ring (see figure 
S10). Nevertheless, the proline-rich 
loop in the dimer conformation still 
protrudes through the space of the half 
ring formed.  
Ribbon format views are shown with 
90o rotation with each monomer 
coloured cyan or brown (above). 
Monomers/proline rich loops in the 
surface surface topology view (left) 
are differently coloured: mauve/red 
and silver/green.  
Supplementary Figure S12. Model Dimers of EBNA1 from the primate LCVs. 
Homodimers were generated using SymmDock for each of the modelled (non-human) 
primate LCV EBNA1 homologues. Monomers are coloured cyan or brown. To the right, the 
C-terminal regions of each (dimerisation and DNA binding domain) are shown enlarged and 
rotated by 90o in the horizontal plane. Note: arrow in cy-EBNA1, structure of the extended 
CK2 binding region. As well as differences in the N-terminal regions, some differences in the 
C-terminal domain structure from the hu-EBNA1 homodimer are apparent. The β barrel of 
the Old World monkey LCV EBNA1 structures is wider compared to hu-EBNA1. The β 
barrel of the ma-EBNA1 dimer is more similar to hu-EBNA1 in terms of symmetry of the 
interacting interface of the monomers.  
CynoEBV-TsBB6 
cy-EBNA1 
CeHV15 
rh-EBNA1 
CeHV12 
ba-EBNA1 
CalHV3 
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Abstract  
 
Epstein-Barr virus (EBV) is a clinically important human virus associated with several 
cancers and is the etiologic agent of infectious mononucleosis. The viral nuclear antigen-1 
(EBNA1) is central to the replication and propagation of the viral genome and likely 
contributes to tumourigenesis. We have compared EBNA1 homologues from other primate 
lymphocryptoviruses (LCV) and found that the central glycine/alanine repeat (GAr) domain, 
as well as predicted cellular protein (USP7 and CK2) binding sites are present in homologues 
in the Old World primates, but not the marmoset; suggesting that these motifs may have co-
evolved. Using the resolved structure of the C-terminal one third of EBNA1 
(homodimerisation and DNA binding domain), we have gone on to develop monomeric and 
dimeric models in silico of the full length protein. The C-terminal domain is predicted to be 
structurally highly similar between homologues, indicating conserved function. Zinc could be 
stably incorporated into the model, bonding with two N-terminal cysteines predicted to 
facilitate multimerisation. The GAr contains secondary structural elements in the models, 
while the protein binding regions are unstructured, irrespective of the prediction approach 
used and sequence origin. These intrinsically disordered regions may facilitate the diversity 
observed in partner interactions. We hypothsise that the structured GAr could mask the 
disordered regions, thereby protecting the protein from default degradation. In the dimer 
conformation, the C-terminal tails of each monomer wrap around a proline-rich protruding 
loop of the partner monomer, providing dimer stability, a feature which could be exploited in 
therapeutic design.  
 
Introduction  
Epstein-Barr virus (EBV, or human herpesvirus 4, HHV4) is a prevalent gammaherpesvirus, 
infecting upwards of 90% of the world population. Primary infection in the very young is 
usually asymptomatic, but in adolescents and adults can cause infectious mononucleosis. 
Infection with EBV is also a risk factor for developing certain autoimmune disorders, 
including multiple sclerosis and systemic lupus erythematosus (1, 2). Importantly, EBV is 
associated with several cancers, including nasopharyngeal carcinoma, Burkitt’s lymphoma 
and Hodgkin’s lymphoma. EBV undergoes a lytic and a latent cycle and the virus persists for 
the lifetime of the host, residing in memory B-cells. During latency, propagation of the 
extrachromosomal viral genome requires the EBV nuclear antigen 1 (EBNA1), a 
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 3 
multifunctional DNA binding protein. EBNA1 plays a role in viral genome replication and is 
essential for its efficient mitotic segregation (3, 4). The protein also acts as a transcriptional 
regulator of both viral and host promoters and may promote lytic reactivation of the virus (5, 
6). Furthermore, multiple lines of evidence indicate that EBNA1 contributes to the 
development of EBV associated tumours through increasing cell proliferation and survival 
and possibly by inducing oxidative stress (7-17). 
EBNA1 binds to DNA as a homodimer in a site-specific manner, recognising a 
consensus 16bp site found multiple times in the viral genome (18-21). The site-specific DNA 
binding and dimerisation domain maps to the C-terminal region of the 641 amino acid 
protein, between residues 459 and 607 (22). EBNA1 can also attach to cellular chromosomes 
non-specifically, mediated through two regions termed linking regions 1 and 2 (LR1 and 
LR2). The N-terminal LR1 (residues 33-89) can be subdivided into two regions: a Gly and 
Arg repeating unit (GR1: residues 33 to 53), which allows the protein to associate with AT-
rich DNA (“AT hook”) and a unique region with multiple Gly then Arg residues, containing 
potential Ser phosphorylation sites and two highly conserved Cys residues. Both sub-regions 
are required for transactivation by the protein (18, 23, 24). LR2 or GR2 (residues 327-377) is 
also a Gly and Arg repeating unit. A host nucleolar protein, EBP2, associates with EBNA1 at 
GR1 and GR2, which might facilitate loading of EBNA1 onto mitotic chromosomes (25, 26). 
Furthermore, it has been proposed that through GR1 and GR2, EBNA1 recruits the origin 
replication complex (ORC) to the viral latent replication orgin (OriP) in an RNA dependent 
manner (27, 28).  
A long Gly/Ala repeat (GAr) sequence (residues 90 to 324) regulates EBNA1 
expression, renders the protein resistant to proteosomal degradation and facilitates immune 
evasion (29, 30). This repeat region retards translation of EBNA1 and, it has been proposed, 
thereby reduces production and processing of misfolded products, thus inhibiting major 
histocompatibility complex (MHC) class I peptide presentation of the protein (31). This idea 
is supported by the observation that cytotoxic T-cell recognition of EBNA1 is largely 
mediated by the presentation of epitopes derived from newly synthesized protein (32). 
However, it is not clear how this function relates to the GAr mediated property of stabilising 
the mature protein (30).  
The structure of a C-terminal domain dimer of EBNA1 (residues 461 to 607) has been 
resolved, co-crystallised binding to the specific DNA recognition sequence, revealing details 
of this interaction and the critical contact residues (33, 34). This C-terminal region 
incorporates four antiparallel  strands, the eight in the dimer forming a barrel-like structure, 
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 4 
with two alpha helices (per monomer) situated outside the  barrel. Two sub-regions were 
described, a flanking region (residues 459-503) and a core domain (residues 504-607), but 
both contribute to sequence specific DNA binding (35).  
EBNA1 associates with multiple host proteins including ubiquitin-specific protease 7 
(USP7), casein kinase 2 (CK2) (36, 37), EBP2 and others (26, 37-41). The core interaction 
sites of EBNA1 with USP7 and CK2 have been determined and map to the central region of 
the protein (37, 42). Most of the protein-protein interactions of EBNA1 map within the 
unresolved N-terminal two thirds of the protein (7, 43), similarly, the contribution of the C-
terminal tail (the last 33 residues) to the protein structure is unknown. 
Given the importance of EBNA1 in the life cycle of this highly medically relevant 
human virus, we aimed to develop a structural understanding of the full length protein. With 
the difficulties in expressing the full length protein, we have generated in silico models of 
EBV EBNA1, in both monomer and homodimer conformations. The model homodimer 
permits prediction of the interaction surfaces and conformation of EBNA1 protein-protein 
interacting regions. Additionally we have generated in silico models of EBNA1 from the 
related primate lymphocryptoviruses (LCV), providing insight into the structural 
morphogenesis of the protein through virus and host co-evolution. 
 
Materials and Methods  
Sequence Retrieval: 
EBNA1 sequences were retrieved from Uniprot (http://www.uniprot.org/) (44). Eight 
complete sequences were available: from human-EBV strains B95-8, AG876 and GD1 (id: 
P03211; Q1HVF7; Q3KSS4), from cynomolgus-EBV (Cyno-EBV or CyEBV), strains Si-IIA 
and TsB-B6 (id: Q9IPQ8 and Q9IPQ9), from rhesus lymphocryptovirus (CeHV15; id: 
O91332), from baboon Cercopithecine Herpesvirus 12 (CeHV12; id: Q80890) and from 
marmoset Callitrichine Herpesvirus 3, (CalHV3; id: Q993H1). 
Multiple Sequence Alignment: 
Sequences were aligned using Clustal X under default parameters (45). Manual adjustments 
were conducted using BioEdit where required. Alignments were visualized using CLC 
sequence viewer 5. 
Phylogenetic Analysis: 
Maximum likelihood trees were constructed using the Whelan and Goldman replacement 
model with 1000 bootstrap replicates in Mega 5.10 (46, 47).  
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Molecular Modelling: 
Structural models were generated using I-TASSER, MOE (http://www.chemcomp.com/) and 
Modeller 9v8 (48, 49). The EBV B95-8 EBNA1 sequence was input to I-TASSER, which 
uses homology modelling where available and unaligned regions are modelled ab initio. 
Cluster centroids were generated using replica exchange Monte-Carlo simulations and by 
averaging all the clustered structure decoys. The structures were refined in terms of global 
topology (49). Models were generated in MOE using the template 1B3T (with and without 
DNA) and ad hoc outgap modelling to similar fragments from PDB for the remainder of the 
sequence, as follows. An initial proposed partial geometry was copied from the template 
chains in the solved structure of 1B3T by using all coordinates where residue identity was 
conserved. Otherwise, only backbone coordinates were used. Based on this initial partial 
geometry, Boltzmann-weighted randomized modelling (50) was employed with segment 
searching in PDB for regions that could not be mapped onto the initial partial geometry (51). 
Each of 25 models was energetically minimized in the AMBER-99 force field (52). The 
highest-scoring intermediate model was determined by generalized Born/volume integral 
(GB/VI) methodology (53). Molecular surfaces were created using the method of Connolly 
(54), as applied within MOE. The best models developed by both approaches were selected 
on the basis of the lowest RMSD deviations with the template (1B3T), lowest free energy and 
atomic clashes. These were used as templates to construct composite models in Modeller 9v8. 
The best composite model (of 50 obtained, all with identical backbone) was selected on the 
basis of normalized Discrete Optimized Molecule Energy (DOPE). This composite model 
was used to generate models for other EBNA1 homologues analysed, using MOE, repeating 
the process described above, by providing query and template primary structure alignment 
and template atomic coordinates as input.  
Structure Assessment: 
FoldIndex and GlobPlot2.3 were used to assess the propensity to form secondary and tertiary 
structures (55, 56). The default parameter for window size in FoldIndex was changed to 10 
residues, to be comparable with GlobPlot2.3.  The models were assessed for their structural 
plausibility using Molprobity (57). This includes generating Ramachandran plots (via 
Rampage: http://mordred.bioc.cam.ac.uk/~rapper/rampage.php), calculation of bad angles and 
bad bonds and atomic clash analysis. In addition models were assessed using Qualitative 
model energy analysis (QMEAN) normalised scoring, using the QMEAN server (58). 
Ubiquitination sites were predicted using CKSAAP UbSite web server (59). Pictorial 
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 6 
representations of structural motifs against the linear sequence were generated in the EMBL 
server PDBsum. 
Dimer Construction: 
EBNA1 dimers were constructed in SymmDock (60) using the composite monomer model as 
input and noted side chain interaction points in the C-terminus from the crystal structure (33). 
SymmDock restricts dimer models to those with a symmetric arrangement. All monomers and 
dimers were visualized in DSvisualizer 3.5. The top 10 dimer conformations, based on 
geometric scores, desolvation energies and the interface area size, as ranked in SymmDock, 
were analysed and superimposed over the 1B3T structure. The dimer with least RMSD to 
1B3T was selected (in each case this proved to be the top ranked dimer model). A full length 
EBNA1 dimer was also constructed in MOE by homology modelling using 1B3T as a dimer 
template and with bound DNA. 
Results  
Phylogeny and sequence alignment of EBNA1 homologues 
EBNA1 of EBV is an unusual protein; with the exception of the GAr region, it shows very 
limited primary sequence similarity to any other protein in the databases. However, there are 
several homologues of EBNA1 found in the related herpesviruses of other primates. Using 
EBNA1 of EBV B95-8 strain (deleting the GAr) in a BLAST search, eight complete EBNA1 
sequences were retrieved, including 3 from different EBV strains and from LCVs infecting 
the cynomolgus monkey (Macaca fascicularis), rhesus macaque (M acaca mulatta), baboon 
genus (Papio) and marmoset family (Callitrichidae). The EBNA1 sequences from these 
viruses are termed here: hu-EBNA1 (from EBV/HHV4), cy-EBNA1 (from CyEBV), rh-
EBNA1 (from CeHV15), ba-EBNA1 (from CeHV12) and ma-EBNA1 (from CalHV3). The 
phylogenetic history of these EBNA1 genes was inferred using the protein sequences, 
revealing the separation of the single New World primate viral sequence (ma-EBNA1) from 
the Old World primate virus sequences (figure 1). Predictably, the hu-EBNA1 sequences are 
closely related and distinct from the other sequences.  
The sequences of the 8 EBNA1 homologues were aligned revealing that the hu-EBNA1 
sequences are highly similar and are the longest amongst the homologues (figure 2 and table 
1). Identity between the Old World monkey LCV EBNA1 sequences ranges between 35% 
and 46%, while ma-EBNA1 (the shortest protein) shows the lowest identity with the other 
EBNA1 sequences (table 1). The GAr of hu-EBNA1 spans 233 residues (90-324) and (in B9-
58) is entirely composed of Gly and Ala residues. The GAr of the Old World monkey viruses 
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is shorter and intervened by other residues (primarily Ser and Val) and it is entirely absent 
from ma-EBNA1.  
The Gly and Arg repeat regions (GR1 and GR2) of hu-EBNA1 (residues 33-53 and 
327-377), which flank the GAr sequence, are present in the Old World primate virus EBNA1 
homologues. However, in the absence of the GAr, ma-EBNA1 has only one GR region 
(aligned to GR2). A sequence adjacent to GR1 in hu-EBNA1 (KRPSCIGCKG) is highly 
conserved in Old World primate LCV EBNA1 but is absent from ma-EBNA1. However, two 
Cys residues in the N-terminal region of ma-EBNA1 (residues 38 and 43), which have been 
aligned to Cys79 and Cys82 of hu-EBNA1 (figure 2), might reflect a conserved function. 
The hu-EBNA1 interaction sites for USP7 and CK2 are conserved in the Old World 
monkey virus EBNA1 homologues. In particular, the residues involved in hydrogen bonding 
between an EBNA1 peptide and USP7 (EBNA1 Pro442, Glu444, Gly445 and Ser447) (42) 
are fully conserved (figure 2). However, this USP7-binding sequence is absent from ma-
EBNA1. The runs of Ser at the CK2 binding site are extended in the Old World monkey LCV 
EBNA1 sequences compared to hu-EBNA1. At the aligned site in the ma-EBNA1 sequence 
are several Ser/Pro residues, but it is not clear if these could constitute a CK2 binding site. 
This suggests that these sequences and their function have either been lost during the course 
of New World monkey viral evolution or gained during Old World monkey viral evolution. 
Between the CK2 and USP7 binding sites is a stretch of approximately 30 residues, similar 
between the Old World monkey viral EBNA1 sequences, but dissimilar to hu-EBNA1.  
There is a single predicted ubiquitination site in hu-EBNA1 (Lys477), which is 
conserved in all the homologues. Out of the 10 proposed phosphorylation sites conserved in 
hu-EBNA1 sequences (61), six are also conserved in most of the primate virus homologues 
(figure 2). The nuclear localisation signal (NLS, 379-385) is completely conserved in EBNA1 
homologues of the Old World primate viruses, but not in ma-EBNA1. A consensus NLS 
signal (K, K/R, x, K/R) is not present within the ma-EBNA1 sequences, however RKxRxxxK 
towards the N-terminus or RKRxxxR at the start of the DNA binding domain might serve as 
an NLS. In ba-EBNA1 and rh-EBNA1, a conserved KKRRS within the LR1 homology region 
could provide a second NLS. 
The most conserved sequence between the EBNA1 homologues is the DNA binding 
and dimerisation domain (residues 459-607) (figure 2). With few exceptions, residues shown 
to be involved in DNA binding or important for interactions in the dimer are identical across 
the homologues (figure 2).  
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 8 
EBNA1 monomeric structure model 
The propensity of hu-EBNA1 to form secondary and tertiary conformation was explored 
using FoldIndex, which predicts that the N-terminal and central regions of the protein are 
unstructured or unfolded (supplemental figure S1). By contrast, the GAr domain yielded a 
positive signal for likely folded conformation and the C-terminal domain shows multiple 
peaks of predicted structure. Similar results were obtained using GlobPlot2.3 (not shown).  
In order to generate a structural model for full length EBNA1 in silico, the hu-EBNA1 
B95-8 sequence was examined for any structural similarities (using PDB Blast) with proteins 
of known structure in the RCSB database. None of the templates thus identified (apart from 
the resolved EBNA1 C-terminal domain), alone or in combination, covered EBNA1 to any 
extent. Therefore, a combined approach to exploit the advantages of three programmes (I-
TASSER, MOE and Modeller) was conducted. I-TASSER uses homology modelling where a 
template is available (1B3T in this case) and for regions where no structure is available, I-
TASSER searches the protein structure databases for small regions of similarity and selects 
several template fragments (supplemental figure S2), threading them into the model, which is 
then evaluated for best fit and the process is iterative. Unaligned regions are modelled ab 
initio and I-TASSER assembles thousands of possible structures which are then selected on 
the basis of multiple parameters (including free energy and Ramachandran plot fit). 
Homology modelling can also be conducted in MOE, which has the advantage of being able 
to restrict the model, in this case using the bound DNA in 1B3T as a required space. MOE 
models unresolved portions of the protein using fragments of high-resolution chains from the 
PDB which superpose well onto anchor residues on either side of the area in question. In 
order to utilise the benefits of both programmes, primary models were generated separately in 
I-TASSER and MOE. The two selected primary models were then used as templates 
employing Modeller to generate a composite structure. The best composite model was 
selected, which showed improved parameter values over both primary models (figure 3 and 
supplemental figure S2, table S1 and model 1). Plausibility of the selected composite model 
was supported by QMEAN score and analysis in Molprobity, which includes an evaluation of 
dihedral bond angles by Ramachandran plot (supplemental figure S3). As expected, the C-
terminal region of the in silico model is almost identical to the 1B3T crystal structure which 
was used in model generation (supplemental figure S4).  
The EBNA1 model predicts a helix towards the N-terminus of the protein (residues 31-
43), within GR1 (figures 2 and 3). A conserved residue within the LR1 transactivation 
domain (Arg71 and also to some extent Arg72) protrudes, horn-like, from the structure. The 
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 9 
GAr region forms multiple helices of varying size, consistent with the FoldIndex and 
GlobPlot2.3 predictions that this region is structured. The remainder of the N-terminal region 
forms un-structured loops and turns, also consistent with the predictions. Similarly, the central 
region of EBNA1 (residues 325-476) incorporating the CK2 and USP7 binding sites, is 
modelled largely as un-structured stretches, with the inclusion of short, parallel  sheets in 
GR2 (residues 334-338, 348-351 and 370-374), in the NLS and in the stretch between the 
CK2 and USP7 core binding sites. A proline rich stretch, well conserved in all the primate 
sequences (residues 537-559), forms a loop (as seen in the crystal structure) which protrudes 
from one side of the model (supplemental figure S4). The acidic C-terminal tail of EBNA1 
(residues 608-641) is predicted to be largely unstructured. In the model, this C-terminal tail 
curls back towards the molecule, making a ring shape (figure 3).  
In order to compare the structural properties of hu-EBNA1 with homologues from the 
related primate viruses, models of the latter were generated using the former as a template in 
MOE (figure 4 and supplemental models 2 to 5). High structural similarity was observed 
between the dimerisation and DNA binding domain of all primate virus EBNA1 homologues. 
Like hu-EBNA1, the C-terminal tail of the other EBNA1 proteins curls to form a ring.  
However, the remainder of the proteins show several differences. With the reduction in length 
of the GAr, GR1 and GR2 become closer. In the absence of the GAr from ma-EBNA1, a 
longer N-terminal alpha helix is predicted. The beta sheets seen in GR2 of hu-EBNA1 are 
reduced or absent in the other modelled structures. The predicted USP7 binding sites remain 
as unstructured regions in the homologues. However, the longer CK2 domains, particularly of 
cy-EBNA1, form  sheets, as does the sequence intervening between this and the USP7 
binding site (supplemental figure S5). Consistent with the models, this region was also 
predicted in the folding propensity plots for cy-EBNA1, rh-EBNA1 and ba-EBNA1 (but not 
hu-EBNA1) as a likely structured region in the middle of the unstructured stretch 
(supplemental figure S1). The prominent Arg71 residue noted in hu-EBNA1, also protrudes 
from the molecule in the modelled ba-EBNA1, but the side chain of the corresponding residue 
in the other homologues is buried within the structure.  
 
EBNA1 homodimer model 
Two approaches were used to generate in silico homodimer models of full-length EBNA1: 
dimer modelling in MOE and dimer generation using SymmDock. The 1B3T resolved C-
terminal domain dimer with bound DNA was used as a template in MOE to generate a full 
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length EBNA1 dimer with DNA (figure 5 and supplemental figure S6 and model 6). Using 
this approach permits incorporation of the DNA molecule into the model and a string of 
residues connecting the C-terminal domain to the N-terminal two thirds of the protein neatly 
sits in the major groove of the bound DNA (figure 5). However, the N-terminal two thirds of 
the protein (and the C-terminal tail), modelled in MOE alone, shows several differences to the 
composite model described above (supplemental figure S7). In addition, this MOE-dimer 
model is not symmetrical, the two monomers showing a different distribution of secondary 
structures, most notably in the C-terminal tail (supplemental figures S6 and S7). This 
asymmetry may simply be a chance effect of the choice of short PDB fragments for the ad 
hoc outgroup modelling, or it may reflect the fact that the DNA structure from 1B3T is used 
as a spatial constraint.  As DNA does not exhibit bilateral symmetry, bound dimers and 
models of bound dimers may also show asymmetry, indeed this has been observed for 
crystallised C-terminal fragments of EBNA1 (62). 
In an alternative approach to generate a dimer structure, the use of SymmDock was 
evaluated.  First a model dimer was generated using a monomer of the resolved EBNA1 C-
terminal domain (a monomer from 1B3T). The dimer model thus generated in SymmDock 
used the correct contacts as in the resolved dimer (table 2) and superimposition of model and 
resolved structure showed that the two were virtually identical (with an RMSD value of 
0.01Å, not shown), thus validating the approach.  Consequently, the in silico composite full 
length monomer model (described above) was used to generate a homodimer in SymmDock, 
inputting the contact residues described for 1B3T. Of the top 20 models generated, the best 
was selected on the basis of lowest free energy (figures 6 and 7 and supplemental model 7). 
The model correctly predicts interaction between the two monomers within the C-terminal 
dimerisation domain. Similarly, the DNA recognition and binding sequences are 
appropriately positioned, relative to the resolved C-terminal domain dimer. The N-terminal 
two thirds of the monomers form perpendicular arms in relation to the dimerisation domain, 
giving a slightly different orientation compared to the MOE-dimer. Superimposition of the 
composite-dimer model over the atomic coordinates of the 1B3T dimer shows a close 
alignment (supplemental figure S8). The predicted hydrogen bonding of the SymmDock-
dimer model includes bonds seen in the C-terminal domain resolved structure, as well as 
between residues that were not in the crystallised fragment  (Table 2 and figure 7).  
While the composite EBNA1 model gives improved structural reliability scores 
compared to either MOE-model produced in the dimer conformation, the composite model 
shows intermolecular clashes with the location where DNA should bind. At present, the DNA 
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molecule cannot be input into I-TASSER as a model constraint. However, the clashing 
residues in the composite-dimer model are unstructured and in vivo are likely to be flexible 
and able to move aside to allow the dimer to bind to DNA. We propose that the composite 
model currently provides the best prediction of the structure of full length EBNA1 (in 
monomer and homodimer configuration) when not bound to DNA. We hypothesize that upon 
binding to DNA through the C-terminal domain, the obstructing unstructured regions move 
aside to allow this and the angle of the N-terminal bulk of the protein, in relation to the C-
terminal domain, may twist as seen in the MOE-dimer model, with the linking peptide strand 
sitting within the DNA major groove. 
Interestingly, the proline rich loop which protrudes out from the monomeric model 
(noted above), in the dimer conformation penetrates into the other monomer, into the ring 
formed by the C-terminal tail and the core domain (figure 6). The proline rich loop was 
observed in the resolved structure (supplemental figure S9), however, in the absence of the C-
terminal tail its significance in the dimer conformation was not previously apparent. This 
feature is also observed in the MOE-dimer model and a GAr deleted-hu-EBNA1 model 
(supplemental figures S6, S10 and S11 and model 8). The “prehensile tail” of one monomer 
wrapping around the proline-rich loop of the other may help to stabilise the dimer. To explore 
this hypothesis, we generated a dimer in SymmDock, using a monomer model deleted for the 
C-terminal tail (deleting residues 608 to 641). Of the top 20 best models (lowest free energy), 
only 8 showed the correct orientation of the two monomers to each other, compared to 15/20 
for the full length sequence. Moreover, the best C-terminal tail deletion dimer model showed 
poorer geometry and energy value scores compared to the full length dimer (supplemental 
table S2), indicating that it is less stable. These data support the prediction that the C-terminal 
tail provides dimer stability.  
EBNA1 dimers form multimers when bound to the repeated DNA recognition sites (the 
family of repeats, FR) at oriP (24).  Two cysteine residues (Cys79 and Cys82) that are highly 
conserved, have been found to coordinate zinc and to facilitate these multimeric interactions. 
Arrayed EBNA1 dimers have been proposed to act cooperatively in transcriptional 
transactivation through FR  (24). In order to explore this structurally, zinc ions were 
introduced into the full length composite dimer model, using MOE. Energy minimisation 
following placement of a zinc ion near Cys79 and Cys82 in each monomer predicted stable 
bonding between the zinc ion and the two cysteines (unlike placement of zinc near the 
proximal His residues, which did not allow bonding). The zinc-bound cysteines sit at the 
distal end of each N-terminal arm of the dimer model (figure 8 and supplemental model 9). 
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From this model it can be envisaged how adjacent dimers might link through zinc (arm to arm 
in an array), the zinc ion being coordinated by four cysteines, two provided by each of the 
adjacent arms of neighbouring dimers. 
Dimers were also generated from each of the EBNA1 monomers of the non-human 
primate LCVs in SymmDock (supplemental figure S12 and models 10 to 13). In each case, 
dimerisation occurs between the C-terminal regions while the N-terminal regions angle away 
from each other.  
 
Discussion  
 
We have compared EBNA1 sequences from different primate LCVs to explore the 
evolutionary history of this viral gene. In addition, we have generated model structures of full 
length EBNA1, a GAr deleted version and dimers of these in silico.  
The phylogenetic tree developed from EBNA1 sequences from related LCVs is 
consistent with the evolutionary history of these viruses inferred from an analysis of DNA 
polymerase and glycoprotein B sequences (63). From this it was proposed that LCVs have co-
evolved with the host, but some evidence of interspecies virus transfer was also apparent (63, 
64). The extensive differences between ma-EBNA1 and hu-EBNA1 (outside of the C-
terminal domain) suggest that EBNA1 has undergone subfunctionalisation since the 
separation of Old and New World primates 43 MYA.  
In silico protein structure modelling tools are becoming ever more sophisticated and as 
a consequence the structures predicted, more reliable (65). Concomitantly, the number of 
resolved structures is rapidly increasing, improving the resources for both template-based 
structure prediction and model assessment. Thus, models with good Molprobity and QMEAN 
scores provide a plausible structure prediction, which is the case for the EBNA1 models 
described here. Nevertheless, the very nature of a model is that veracity cannot be guaranteed. 
Despite this, consistently observed features in these models allow conclusions to be drawn 
and hypotheses made.  
All the models generated in this study, irrespective of the prediction approach and the 
EBNA1 strain sequence used, model the N-terminal two thirds of the protein as a region with 
unstructured stretches, distinct from the C-terminal domain. This prediction is accordant with 
the resolved C-terminal structure and the MOE-dimer model incorporating DNA, which show 
that the N-terminal region is linked to the C-terminal domain via a string of residues that sit in 
the DNA major groove, thus separating the two protein regions by the DNA strand. The C-
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terminal DNA binding and dimerisation domain is well conserved and predicted to be 
structurally highly similar between the EBNA1 homologues, suggesting a conservation of 
action in homodimerisation and sequence specific DNA binding. Introduction of zinc ions 
into the dimer model predicts stable binding to Cys79 and Cys82 (conserved in all 
homologues), which could facilitate self-association of an array of EBNA1 dimers (figure 
8E). This is consistent with the observation that these residues are required for cooperative 
transactivation requiring zinc (24) and that deletion of LR1 from hu-EBNA1 significantly 
impairs the transactivation function (23). 
Both GR1 and GR2 sequences of hu-EBNA1 are involved in binding to EBP2, G-rich 
RNA and recruitment of ORC and are required for stimulation of EBNA1 dependent viral 
genome replication, tethering to metaphase chromosomes and the efficient segregation of 
viral genomes (26, 27). Sequence and structural conservation of these regions in the EBNA1 
homologues suggest a functional conservation in viral genome propagation and maintenance. 
The single GR region in ma-EBNA1 may reflect a more ancestral form that has not been split 
in two by incorporation of the GAr domain (the latter is absent from ma-EBNA1). Ma-
EBNA1 also lacks the consensus NLS, however, its likely role in viral genome propagation 
suggests nuclear localisation might be mediated via another sequence (as described above).  
In all of the EBNA1 homologues, the short proline-rich tract within the C-terminal 
domain is conserved. In the resolved structure this forms a loop jutting out from the molecule 
and this feature is recapitulated in all of the models. Interestingly, in all of the dimer models, 
this loop of each monomer slots into the space formed between the C-terminal tail and core 
domain of the other monomer, forming an interlocking structure in the manner of a “dowel 
pin joint”. Moreover, a dimer model generated lacking the C-terminal tail shows energy 
values indicative of reduced stability in comparison to the full length dimer. Although the C-
terminal tail is not essential for dimer formation, the tail of each monomer (prehensile-like) 
curling around the dowel pin of the other, may act to stabilise the dimer. Importantly, this 
information could be used in designing therapeutic agents to disrupt EBNA1 dimerisation and 
hence action. 
The USP7 core binding site is highly conserved in the Old World primate LCV EBNA1 
sequences, and it seems likely that they bind to host USP7. The extended CK2 binding site in 
the Old World monkey sequences, could reflect differences in host CK2 or that these proteins 
bind to CK2 with different affinity. Alternatively, the longer, more structured site (compared 
to hu-EBNA1) might confer another property. Ma-EBNA1 appears to lack both sites. As 
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more LCV EBNA1 sequences become available, it will be interesting to determine if these 
domains and the GAr were acquired and evolved together. 
All the models of EBNA1 predict that the protein interactions sites (with EBP2, USP7 
and CK2) are intrinsically unstructured or disordered. Such regions could provide molecular 
flexibility, allowing for rapid association/dissociation, promiscuity in partner interactions and 
increased availability to modification (66-68). Proteins with signalling or transcriptional 
regulatory functions appear to be enriched with intrinsically disordered segments, probably 
because this permits a greater repertoire of specific interactions (69). Indeed, EBNA1 
interacts with multiple partners and the interaction sites in some cases overlap (e.g. with 
EBP2 and RNA), or the core binding sites are in close proximity (e.g. CK2 and USP7). Thus 
while core binding sites may confer specificity in partner interactions, it is possible that 
EBNA1 can adopt different shapes with different partners. Thus, excluding the more 
structured regions, the model predicted here may reflect a “resting” shape, which in the living 
cell can mould to accommodate a variety of partner molecules. 
Intrinsically disordered proteins (IDPs) tend to be tightly regulated, their efficient 
proteosomal degradation (ubiquitin-dependent and independent) being critical to the health of 
the cell (70). It has been proposed that IDPs are susceptible to default degradation by the 20S 
proteasome (ubiquitin independent) and that disordered regions of a protein must be masked 
in order to avoid rapid degradation; thus newly synthesized IDPs are at higher risk of 
degradation (70, 71). Despite the predicted disordered regions in EBNA1, the protein is 
highly stable in B-cells (over 30 hours) (72), suggesting that disordered regions are masked. 
Cytotoxic T-cell recognition of EBNA1 is largely mediated by the presentation of epitopes 
derived from newly synthesized protein (32). This would be consistent with EBNA1 having 
disordered regions susceptible to default degradation immediately post synthesis. The 
observed stability of EBNA1 may result from either rapid complex formation, post 
translational modification, or be due to some other masking activity. Based upon current 
knowledge and our modelling studies, we propose that the GAr might perform such a 
masking function.  
Predictions of the propensity of EBNA1 to fold suggest that the GAr is structured; the 
composite model predicts that the region forms several alpha helices and the MOE-dimer 
model predicts a mixture of helices and  sheets. Earlier studies proposed that the GAr might 
form -sheets (73). More recently it has been determined that Ala residues have a strong 
propensity to form  helical and break  strand conformations. Although Gly residues 
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examined alone tend to break both conformations, in conjunction with Ala residues, Gly 
shows a strong propensity to form alpha helices (74), supporting the predictions of our 
models. 
The hu-EBNA1 GAr sequence renders EBNA1 resistant to proteosomal degradation 
and inhibits self-synthesis, resulting in impaired immune presentation (30, 31). However, the 
length and purity of the repeat has a profound effect upon is action. The smaller, impure GAr 
of rh-EBNA1 and ba-EBNA1 confer little or no self-synthesis inhibition, but nevertheless 
these proteins are stable, with a half-life similar to hu-EBNA1 (72). In addition, rh-EBNA1 
expressing cells are more efficiently recognised by cytotoxic T-cells and the epitopes are 
derived from newly synthesized protein (72). It has been proposed that by retarding 
translation, the hu-GAr sequence reduces the generation of misfolded products which would 
otherwise be processed and presented by MHC (31). In an extension to this hypothesis, we 
propose that the partially structured GAr sequence masks the disordered regions of EBNA1, 
thereby inhibiting default degradation by the 20S proteasome. Several observations are 
consistent with this hypothesis; 1) retarded translation might allow the GAr to fold in advance 
of translation of the disordered central region inhibiting early default degradation; 2) GAr 
masking of the disordered regions would continue to protect the mature protein from 
degradation; 3) GAr masking would not override ubiquitin mediated degradation, consistent 
with observations (73); 4) the hypothesis allows for separation of two functions of GAr, 
retarding translation and conferring protein stability, which has been observed experimentally 
for hu-EBNA (31) and would explain the observed differences in activity between hu-EBNA1 
and the rh-EBNA1 and ba-EBNA1 proteins. This hypothesis is also consistent with the 
possibility that evolutionary acquisition of disordered regions (such as the USP7 and CK2 
binding regions), necessitated co-acquisition of a masking function.  
EBNA1 is the only viral protein consistently expressed in all proliferating EBV infected 
cells and thus represents a key therapeutic target. As such, knowledge of its structure and 
interactions will contribute to the understanding of viral biology and also aid in the design of 
potential anti-viral drugs. 
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Legends to Figures 
Figure 1 
Phylogenetic tree of EBNA1. The evolutionary history of the LCV EBNA1 genes was 
inferred using the encoded amino acid sequences, employing the maximum likelihood method 
with the Whelan and Goldman replacement model. The consensus phylogenetic tree compiled 
from 1000 bootstrap replicates shows the support percentages at each node. One clade 
comprises three EBV homologues of EBNA1 (hu-EBNA1). Other EBNA1 sequences from 
non-human primate LCVs form a separate clade (herpesviruses from cynomolgous monkey 
(CyEBV), rhesus macaque (CeHV15) and baboon (CeHV12)), while the marmoset CalHV3 
EBNA1 homologue outgroups both clades. A schematic representation of the domain 
structure of selected EBNA1 molecules is shown on the right (with amino acid length 
indicated). The predicted protein domains or sites are colour coded: purple: Gly, Arg repeat 
regions (GR1 and GR2), yellow: GAr, orange: NLS, cyan: CK2 binding site, red: USP7 core 
binding site, green: DNA binding domain (core in dark green).  
 
Figure 2 
Multiple sequence alignment of EBNA1. The amino acid alignment of EBNA1 homologues 
of human and other primate LCVs is shown using EBNA1 of EBV B95-8 strain as the 
reference sequence, with Rasmol colour coding of residues. The secondary structural 
elements (based on the composite model of EBV-B95-8) are shown above as arrows ( 
sheets) and cylinders ( helices). Selected protein domains or interaction sites are indicated 
by coloured horizontal bars: purple: GR1 and GR2, yellow: GAr, orange: NLS (379-385, 
KRPRSPS), cyan: CK2 binding site, red: USP7 binding site, green: DNA binding domain 
(core in dark green). Coloured dots above the sequence indicate other noted residues: blue: 
predicted phosphorylation sites (note conservation of Ser60, Ser62, Ser78, Ser365, Ser383, 
Ser393); pink: critical residues involved in USP7 binding; purple: dimerisation; green: DNA 
binding (note conservation of residues involved in DNA binding: Lys514, Thr515, Tyr518, 
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Asn519, Arg521 and Arg522 and dimer interactions: Arg469, Tyr510, Arg532, Leu533, 
Phe541, Gly542, Pro553, Glu556, Tyr561, Val597, Ser599, Asp601, Asp602, and Asp605) .  
 
Figure 3  
EBV EBNA1 composite model structure. A composite model structure of EBV B95-8 
EBNA1 was generated using I-TASSER, MOE and Modeller and is presented in A-C, with 
180
o 
rotation in D-F. (A, D) Ribbon diagram, indicating the region which has been resolved 
from the crystal structure (1B3T) boxed. (B, E) Electrostatic surface diagrams. (C) Surface 
topology with highlighted structural and/or functional domains (as defined in figure 2): 
yellow: GAr; purple: GR1 and GR2; pink: Arg71 and Arg72; cyan: CK2 interaction region; 
orange: NLS; red: USP7 binding site; light green and dark green: flanking region and core 
DNA binding and dimerisation domain. Note, the C-terminal acidic tail (arrow in A) loops 
round to form a “ring” with the C-terminal region of the molecule.  
 
Figure 4 
Primate LCV EBNA1 structures. The modelled structures of EBNA1 monomers from 
different primate LCVs (as indicated) are shown from 2 angles (180
o
 rotation) in ribbon 
format. Structural and/or functional domains as they relate to EBV EBNA1 are colour coded 
as in figure 3.  
 
Figure 5 
EBV EBNA1 MOE dimer model structure. A ribbon diagram of the EBV B95-8 EBNA1 
MOE dimer model is depicted with bound DNA (yellow) shown in surface topology. Note the 
string of residues connecting the C-terminal domain with the remainder of the protein sitting 
in the DNA major groove.  
 
Figure 6 
EBV EBNA1 composite model dimer structure.  (A): Ribbon diagram of the EBV B95-8 
EBNA1 composite dimer model is shown with the monomers coloured cyan or brown. The C-
terminal region involved in homodimerisation, DNA recognition and binding is enlarged and 
rotated by 90
o
 in the horizontal plane in (B) and viewed from the “top” (C). The central barrel 
can be clearly viewed in (B). In (C), the penetrating loop and DNA binding core domain are 
indicated for each monomer. (D and E): Surface topology diagrams of the monomer and 
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dimer (respectively), showing the penetrating loop, residues Phe541-Lys555 coloured red or 
green.  
 
Figure 7  
Contacts in the EBNA1 composite dimer model.  The hydrogen bond pattern between the 
two EBNA1 monomers (cyan and brown) is shown.  Black dashed lines represent hydrogen 
bonds and the interacting amino acids are labelled. 
 
Figure 8  
Zinc in the EBNA1 composite dimer model.  Stable bonding between zinc (green) and 
Cys79 and Cys82 (red ball and stick) is predicted in the EBNA1 full length dimer model, 
shown in ribbon format with 90
o
 rotation in the vertical plane between (A) and (B). (C and 
D): Enlarged image of interaction as seen in (B). E: A cartoon of zinc linked EBNA1 dimers 
bound to DNA. 
 
Table 1 
 EBV 
GD1 
EBV 
AG876 
CEBV 
TsbB6 
CEBV 
SiIIA 
CeHV15 CeHV12 CalHV3 
EBV B958 97 88 46 44 38 36 22 
EBV GD1  87 46 43 38 36 22 
EBV AG876   44 42 37 35 21 
CEBV TsbB6    90 54 47 21 
CEBV SiIIA     56 50 23 
CeHV15      59 25 
CeHV12       26 
 
Table 1. Percentage sequence identity matrix of EBNA1 homologues  
 
Table 2 
 
No. 1B3T SymmDock-dimer model Gly/Ala deleted model 
1  NS NF Lys313-Arg314 (x2) 
2  NS  Glu367-Arg368 (x2)  NF 
3  NS  Arg370-Ser386  NF 
4  NS  Arg382-Asp455  NF 
5  NS  Ser386-Asp455  NF 
6  Arg469-Glu556 (x2)  NF  Arg469-Glu556 
7  Tyr510-Asp605 Tyr510-Trp609 * Tyr510-Asp605 
8  NS Tyr510-Phe610 * NF 
9  NF NF Arg521-Pro553 (x2) 
10  Arg532-Gly542 (x2)  Arg532-Gly542 (x2)  Arg532-Met543 (x3) * 
11  Arg532-Phe541  NF  Arg532-Gln550 * 
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12  Leu533-Pro553  Leu533-Pro553  NF 
13  Gly542-Pro607  NF  NF 
14  NF NF Ala544- Glu641 
15  NF NF Arg555-Gly470 (x2) 
16  NF Ile558-Glu629 (x2)  NF 
17  Tyr561-Tyr561  Tyr561-Trp609 * Tyr561-Tyr561 
18  NF NF Ala588-Asp625 
19  NF NF Cys591-Asp625 
20 Arg594-Asp605  Arg594-Pro608 * NF  
21 NS Arg594-Phe610  NF  
22 Thr596-Asp602 NF  NF  
23 Val597-Asp601  NF  NF  
24 Ser599-Ser599 NF  NF 
 
Table 2. Comparison of intermolecular hydrogen bond pattern between the EBNA1 
composite dimer model, the GAr deleted model and the resolved C-terminal domain 
structure. Intermolecular hydrogen bonds observed in 1B3T (residues 461-607), the full 
length composite EBNA1 SymmDock-dimer model (residues 1-641) and the GAr deleted 
(missing residues 91 to 327 inclusive) EBNA1 dimer model are listed. In the latter, residues 
are numbered according to the full length protein. Residues sharing more than one bond are 
indicated (x2 or x3). NS: not structured; NF: not found; * denotes a difference in bond partner 
compared to 1B3T. 
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